Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
79.67
+0.56 (+0.71%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
↗
March 16, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
↗
February 21, 2023
Via
Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
↗
February 21, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
↗
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Analyst Expectations for Ionis Pharmaceuticals's Future
↗
January 19, 2023
Via
Benzinga
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
The Latest Analyst Ratings for Ionis Pharmaceuticals
↗
December 21, 2022
Via
Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
December 13, 2022
Via
Benzinga
4 Analysts Have This to Say About Ionis Pharmaceuticals
↗
November 10, 2022
Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:
Via
Benzinga
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
↗
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday
↗
November 10, 2022
Via
Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
↗
November 04, 2022
Via
Benzinga
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs
↗
September 07, 2022
Via
Benzinga
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss
↗
August 09, 2022
The guidance stayed intact despite a wide second-quarter flop.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
↗
December 21, 2022
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
3 Biotech Stocks to Sell in October
↗
September 29, 2022
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.
Via
InvestorPlace
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
↗
September 29, 2022
Patients didn't show any improvements in a study meant to test multiple drugs.
Via
Investor's Business Daily
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
↗
September 23, 2022
Though successful in early testing, it wasn't enough to win a Phase 3 study.
Via
Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
↗
September 23, 2022
Via
Benzinga
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
↗
September 09, 2022
Via
Benzinga
Analyst Ratings for Ionis Pharmaceuticals
↗
September 09, 2022
Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
↗
September 09, 2022
Upgrades
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
↗
September 07, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
↗
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ionis Pharmaceuticals: Q2 Earnings Insights
↗
August 09, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Moderna, PayPal And Some Other Big Gainers From Wednesday
↗
August 04, 2022
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
↗
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
↗
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
